Aromasin 25 mg coated tablets
- Name:
Aromasin 25 mg coated tablets
- Company:
Pfizer Healthcare Ireland
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 02/10/20
(Click to Download)Click on this link to Download PDF directly
Pfizer Healthcare Ireland
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 2 October 2020 PIL
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 31 January 2019 PIL
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - excipient warnings
- Change to section 4 - possible side effects
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
Updated on 31 January 2019 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 6.1 - List of excipients
- Change to section 6.6 - Special precautions for disposal and other handling
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The following changes to the labelling have been approved. Please refer to attached copy/copies of labelling documentation for full details.
The SPC has been updated as follows:
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Update in line with QRD wording
4.3 Contraindications
Section updated to revise paragraph for readability purposes
4.4 Special warnings and precautions for use
Methyl-p-hydroxybenzoate updated to methyl parahydroxybenzoate
4.5 Interaction with other medicinal products and other forms of interaction
Wording within section updated from drugs to medicinal products
4.6 Fertility, pregnancy and lactation
Administrative update
4.7 Effects on ability to drive and use machines
New statement added:
Exemestane has moderate influence on the ability to drive and use machines.
4.8 Undesirable effects
Reporting details updated
6.1 List of excipients
Methyl-p-hydroxybenzoate updated to methyl parahydroxybenzoate
6.6 Special precautions for disposal and other handling
Section revised to;
No special requirements for disposal.
Updated on 26 June 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 5 - how to store or dispose
- Change to section 6 - date of revision
- Improved presentation of PIL
Updated on 2 January 2018 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 2 January 2018 SPC
Reasons for updating
- Change to section 5.3 - Preclinical safety data
- Change to section 5.1 - Pharmacodynamic properties
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
5.1. Pharmacodynamic properties – Section updated to include the 10-year final follow-up results from the Intergroup Exemestane Study (IES) 96 OEXE-031 (A5991012).
5.3. Preclinical safety data – The MHRA requested to consider omitting the proposed addition to this section therefore no update has been made. (i.e. no change to the currently approved version for Section 5.3).
Updated on 16 July 2015 SPC
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.1 - List of excipients
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows
4.1. Therapeutic indications – Section updated in line with QRD
4.2. Posology and method of administration – Section updated in line with QRD
4.3. Contraindications - Section updated in line with QRD
4.4. Special warnings and precautions for use - Section updated with date on osteoporosis and Vitamin D supplementation
4.5. Interaction with other medicinal products and other forms of interaction - Section updated in line with QRD
4.6. Fertility, pregnancy and lactation - Section updated in line with QRD
4.8. Undesirable effects - section updated in line with QRD and to include data in line CDS
5.1. Pharmacodynamic properties - Section updated in line with QRD
5.2 Pharmacokinetic properties - Section updated in line with QRD
5.3. Preclinical safety data – Section updated to improve electronic presentation
6.1. List of excipients - Section updated to improve electronic presentation
Updated on 15 July 2015 PIL
Reasons for updating
- New PIL for new product
Updated on 15 July 2015 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to storage instructions
- Change to side-effects
- Change to date of revision
- Change to dosage and administration
- Change to improve clarity and readability
Updated on 31 January 2013 SPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 5.1
The SPC was updated to reflect the updated efficacy and safety data of exemestane for the adjuvant treatment of women with EBC obtained from the primary and secondary end point analysis of the 96-OEXE-031 Main Study at 87-Months follow-up and the final analyses of the 96-OEXE-031 Bone Substudy.
The safety results from the 87-months follow-up study confirm the safety profile of the product is unchanged. Thus no safety updates are herewith included in the Summary of Product Characteristics.
Section 4.8
The addition of “Intergroup Exemestane Study (IES)” is included in the introductory text of section 4.8 to detail the origin of adverse event data.
Updated on 22 June 2012 SPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - MA number
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 19 June 2012 PIL
Reasons for updating
- Change of licence holder
- Change to date of revision
- Change to marketing authorisation holder
Updated on 19 October 2011 SPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 18 October 2011 PIL
Reasons for updating
- Change to date of revision
- Change to MA holder contact details
Updated on 1 August 2011 PIL
Reasons for updating
- Correction of spelling/typing errors
Updated on 31 July 2009 SPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 29 July 2009 PIL
Reasons for updating
- Change to side-effects
Updated on 12 November 2008 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to further information section
Updated on 11 November 2008 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 6.1 - List of excipients
- Change to section 6.4 - Special precautions for storage
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 9 - Date of renewal of authorisation
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 2: Clarity on what the tablet contains.
Section 4.6: Section updated with information on women with child-bearing potential
Section 4.8: Updated with further data.
Section 6.1: Section edited.
Section 6.4: Updated statement on storage.
Section 6.6: Heading updated as per current QRD template.
Section 9: date updated with renewal approval
Updated on 30 April 2008 PIL
Reasons for updating
- Improved electronic presentation
- Change to drug interactions
Updated on 3 October 2007 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.4 – Update on osteoporosis and reformatting
4.8 – Side effects: Osteoporosis and fracture added. Section also updated to reflect safety results
5.1 – efficacy results updated
Updated on 7 August 2006 PIL
Reasons for updating
- Change of manufacturer
- Change to date of revision
Updated on 31 July 2006 PIL
Reasons for updating
- Change of manufacturer
Updated on 6 October 2005 PIL
Reasons for updating
- Change to, or new use for medicine
- Change to warnings or special precautions for use
- Change to side-effects
Updated on 6 October 2005 SPC
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 3 August 2005 SPC
Reasons for updating
- Change to section 5.3 - Preclinical safety data
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 21 March 2005 SPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 3 - Pharmaceutical form
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 6.4 - Special precautions for storage
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - MA number
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 28 February 2005 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 20 February 2004 SPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 26 June 2003 SPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Product subject to medical prescription which may not be renewed (A)